NEW YORK (GenomeWeb News) – NextGen Sciences said today that it has sold its electrophoresis business to Sigma-Aldrich for an undisclosed sum.

The Ann Arbor, Mich.-based company said the deal is part of its strategic realignment plan to pare back its operations and focus on its biomarker services.

Under this agreement, Sigma-Aldrich has acquired NextGen's automated gel casting unit, the a2DEoptimizer, and its large format pre-cast gels for a cash payment and royalties based on revenues over three years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.